PPARG Antikörper (N-Term)

Produktnummer ABIN966886

Produktdetails anti-PPARG Antikörper

Target: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Bindungsspezifität: N-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PPARG Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Kreuzreaktivität (Details): No cross reactivity with other proteins.

Produktmerkmale: Rabbit IgG polyclonal antibody for Peroxisome proliferator-activated receptor gamma ( PPARG) detection. Tested with WB in Human.

Immunogen: A synthetic peptide corresponding to a sequence at the N-terminal of human PPAR-G, different from the rat and mouse sequences by two amino acids.< br/>Immunogen was affinity purified.

Isotyp: IgG

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Add 0.2 mL of distilled water will yield a concentration of 500 µg/mL.

Buffer: Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Thimerosal, 0.05 mg Sodium azide.

Konservierungsmittel: Sodium azide, Thimerosal (Merthiolate)

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: At -20 °C for one year. After reconstitution, at 4 °C for one month. It can also be aliquotted and stored frozen at -20 °C for a longer time.

Referenzen für anti-PPARG Antikörper (ABIN966886)

Ameshima, Golpon, Cool, Chan, Vandivier, Gardai, Wick, Nemenoff, Geraci, Voelkel: "Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth." in: Circulation research, Vol. 92, Issue 10, pp. 1162-9, (2003) (PubMed).

Berger, Moller: "The mechanisms of action of PPARs." in: Annual review of medicine, Vol. 53, pp. 409-35, (2002) (PubMed).

Deeb, Fajas, Nemoto, Pihlajamäki, Mykkänen, Kuusisto, Laakso, Fujimoto, Auwerx: "A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity." in: Nature genetics, Vol. 20, Issue 3, pp. 284-7, (1998) (PubMed).

Details zu PPARG

Target: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Abstract: PPARG Produkte

Synonyme: PPAR gamma antikoerper, PPARg2 antikoerper, PPARG antikoerper, Nr1c3 antikoerper, PPAR-gamma antikoerper, PPAR-gamma2 antikoerper, PPARgamma antikoerper, PPARgamma2 antikoerper, NR1C3 antikoerper, CIMT1 antikoerper, GLM1 antikoerper, PPARG1 antikoerper, PPARG2 antikoerper, xPPAR-gamma antikoerper, PPAR-GAMMA antikoerper, PPARGAMMA antikoerper, peroxisome proliferator-activated receptor gamma antikoerper, peroxisome proliferator activated receptor gamma antikoerper, peroxisome proliferator activated receptor gamma L homeolog antikoerper, PPARG antikoerper, Pparg antikoerper, pparg.L antikoerper

Hintergrund: The peroxisome proliferator-activated receptors (PPARs) are a group of three nuclear receptor isoforms, PPAR gamma, PPAR alpha, and PPAR delta, encoded by different genes. PPARs are ligand-regulated transcription factors that control gene expression by binding to specific response elements (PPREs) within promoters. PPAR gamma is a transcription factor that has a pivotal role in adipocyte differentiation and expression of adipocyte-specific genes. The PPAR gamma1 and gamma2 isoforms result from alternative splicing and have ligand-dependent and -independent activation domains. PPAR gamma is a member of a family of nuclear receptors/ligand-dependent transcription factors, which bind to hormone response elements on target gene promoters. Ameshima et al. (2003) found that PPAR gamma is abundantly expressed in normal lung tissues, especially in endothelial cells, but that its expression is reduced or absent in the angiogenic plexiform lesions of pulmonary hypertensive lungs and in the vascular lesions of a rat model of severe pulmonary hypertension. And they conclude that fluid shear stress decreases the expression of PPARgamma in endothelial cells and that loss of PPARgamma expression characterizes an abnormal, proliferating, apoptosis-resistant endothelial cell phenotype.

Pathways: MAPK Signalweg, Nuclear Receptor Transcription Pathway, Steroid Hormone Mediated Signaling Pathway, Negative Regulation of Hormone Secretion, Carbohydrate Homeostasis, Regulation of Lipid Metabolism by PPARalpha, Positive Regulation of Endopeptidase Activity, Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation